Not Signed In -
Ondansetron |
Zofran |
Ondansetron Systematic (IUPAC) name 9-methyl-3-[(2-methyl-1H-imidazol-1-yl) methyl]-1,2,3,9-tetrahydrocarbazol-4-one Identifiers CAS number 99614-02-5 ATC code A04AA01 PubChem 4595 DrugBank APRD00481 Chemical data Formula C18H19N3O Mol. weight 325.9 g/mol Pharmacokinetic data Bioavailability ~60% Protein binding 70%-76% Metabolism Hepatic (CYP3A4, CYP1A2, CYP2D6) Half life 5.7 hours Excretion Renal Therapeutic considerations Pregnancy cat. B1 ...
Wikipedia - [full article]
Ondansetron Clinical Trials
- Ondansetron for the Treatment of Methamphetamine Dependence - 1
ClinicalTrials.gov Identifier: NCT00040053 - Active, not recruiting
Amphetamine-Related Disorders
- Drug Treatment for Alcoholism (ondansetron)
ClinicalTrials.gov Identifier: NCT00006205 - Recruiting
Alcoholism
- The Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
ClinicalTrials.gov Identifier: NCT00149734 - Recruiting
Schizophrenia
- Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
ClinicalTrials.gov Identifier: NCT00006348 - Active, not recruiting
Leukemia; Lymphoma; Multiple Myeloma; Eye Cancer
- Ondansetron for the Treatment of Cocaine Dependence - 1
ClinicalTrials.gov Identifier: NCT00033085 - Active, not recruiting
Cocaine-Related Disorders; Drug Administration Schedule
- Oral Disintegrating Ondansetron Tablet to Reduce Vomiting from Gastroenteritis in a Pediatric Emergency Department
ClinicalTrials.gov Identifier: NCT00120744 - Active, not recruiting
Gastroenteritis; Vomiting; Diarrhea; Dehydration
- Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen
ClinicalTrials.gov Identifier: NCT00016380 - Active, not recruiting
Endocrine Cancer; female reproductive cancer; Gastrointestinal Cancer; nausea and vomiting; Quality of Life
- Aprepitant, Ondansetron, and Dexamethasone in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00248547 - Active, not recruiting
Cancer
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
ClinicalTrials.gov Identifier: NCT00437229 - Active, not recruiting
Healthy Adult Volunteer
- Combined Pharmacotherapies for Alcoholism (naltrexone/ondansetron)
ClinicalTrials.gov Identifier: NCT00027079 - Completed
Alcoholism
- Ondansetron Treatment for Alcoholism
ClinicalTrials.gov Identifier: NCT00000443 - Completed
Alcoholism
- Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
ClinicalTrials.gov Identifier: NCT00005994 - Active, not recruiting
nausea and vomiting
- Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00314743 - Recruiting
Nausea; Vomiting
- Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00285272 - Recruiting
Chemotherapy Induced Nausea and Vomiting; Non-Hodgkins Lymphoma; Multiple Myeloma
- Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
ClinicalTrials.gov Identifier: NCT00003817 - Active, not recruiting
unspecified adult solid tumor, protocol specific; Quality of Life; nausea and vomiting
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
ClinicalTrials.gov Identifier: NCT00499668 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
- Toxicity Substudy of ESPRIT: TOXIL-2 Substudy
ClinicalTrials.gov Identifier: NCT00147355 - Recruiting
rIL-2-toxicity; interleukin-2 therapy; HIV
- Ondansetron Reduce Vomiting Associated With Ketamine PSA
ClinicalTrials.gov Identifier: NCT00387556 - Completed
Conscious Sedation
- Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
ClinicalTrials.gov Identifier: NCT00040742 - Recruiting
nausea and vomiting; unspecified adult solid tumor, protocol specific
- Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)
ClinicalTrials.gov Identifier: NCT00199329 - Completed
Postoperative Nausea and Vomiting
- Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking
ClinicalTrials.gov Identifier: NCT00183222 - Completed
Alcohol Dependence
- Post Burn Pruritus Study
ClinicalTrials.gov Identifier: NCT00137202 - Completed
Itching
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
ClinicalTrials.gov Identifier: NCT00018850 - Completed
Schizophrenia
- Role of Metabolites in Nicotine Dependence (3) - 6
ClinicalTrials.gov Identifier: NCT00000289 - Completed
Tobacco Use Disorder
- A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department
ClinicalTrials.gov Identifier: NCT00429832 - Completed
Nausea; Vomiting
- Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
ClinicalTrials.gov Identifier: NCT00285051 - Suspended
Cancer
- Dexamethasone and Ondansetron or Palonosetron in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy for Early-Stage Breast Cancer
ClinicalTrials.gov Identifier: NCT00343863 - Suspended
Breast Cancer; Nausea and Vomiting
- Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
ClinicalTrials.gov Identifier: NCT00020657 - Completed
unspecified adult solid tumor, protocol specific; nausea and vomiting; Quality of Life
Resources
- Ondansetron (Drug Digest)
- Zofran (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
